Literature DB >> 16464759

Skin lesions induced by bortezomib.

Ludek Pour1, Roman Hajek, Adam Zdenek, Marta Krejci, Andrea Krivanova, Jiri Vorlicek.   

Abstract

We report on six cases of skin lesions induced by bortezomib in patients treated for relapsed multiple myeloma. The folliculitis-like rash appeared in the second cycle of bortezomib therapy. Therapy with prednisone led to rapid resolution of the skin lesions. Prednisone 10 mg before each infusion of bortezomib was necessary to prevent recurrence of the rash while antihistamines alone were ineffective.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16464759

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  3 in total

1.  Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.

Authors:  Tomohiko Kamimura; Toshihiro Miyamoto; Shuichiro Takashima; Noriko Yokota; Yong Chong; Yoshikiyo Ito; Koichi Akashi
Journal:  Int J Hematol       Date:  2012-09-08       Impact factor: 2.490

2.  Ixazomib-induced cutaneous necrotizing vasculitis.

Authors:  A Alloo; H Khosravi; S R Granter; S M Jadeja; P G Richardson; J J Castillo; N R LeBoeuf
Journal:  Support Care Cancer       Date:  2018-02-01       Impact factor: 3.603

3.  Recurrent Body Rash Warranted Second Desensitization With Acyclovir in a Myeloma Patient: A Case Report.

Authors:  Jack T Seki; Pamela Ng; Wallace Lam; Julie Cote; Anca Prica
Journal:  J Clin Med Res       Date:  2017-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.